NIA Study Confirms Protandim Nrf2 Synergizer Extends Life
(Thomson Reuters ONE) -
New Study from the National Institute of Aging Interventions Testing Program
(NIA ITP) Shows Protandim Significantly Extends Lifespan in Male Mice
SALT LAKE CITY, Aug. 02, 2016 (GLOBE NEWSWIRE) -- A new study sponsored by the
NIA ITP and published in Aging Cell found what developers and users of
LifeVantage have held to be true for a very long time.
As part of the NIA ITP federally-funded program that examines treatments with
the "potential to extend lifespan and delay disease and dysfunction," and
thereby extend lifespan, researchers provided the supplement Protandim(®), the
Nrf2 Synergizer(®) to male mice in a rigorous and carefully controlled study.
The result: Protandim was proven to "significantly increase the lifespan of male
mice, with a 7 percent increase in median survival." The findings on female mice
were less dramatically conclusive, showing an increase in lifespan of 3 percent.
Since the NIA ITP program's inception in 1999, Protandim is the only nutritional
supplement tested that has been proven to increase the median survival in mice,
thus delaying the aging process.
Protandim was chosen for testing based on positive indications on its ability to
suppress tumor-promoting oxidative stress, cell proliferation and inflammation,
and the ability to protect the heart from oxidative stress and fibrosis in
studies published prior to 2010. Some of the other recognized nutritional
substances tested included fish oil, curcumin, green tea and resveratrol. None
of these individual ingredients were shown to increase the lifespan of mice.
"We are extremely excited about these results from the NIA ITP study and are
enthusiastic about the continued advancement of the research and findings that
demonstrate Protandim's veracity and effectiveness in additional studies to
come," said LifeVantage President and Chief Executive Officer Darren Jensen.
For more information about the Protandim results in the NIA's study, readers
can click here or
visit: http://onlinelibrary.wiley.com/doi/10.1111/acel.12496/abstract.
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq:LFVN), is a science based network marketing
company dedicated to visionary science that looks to transform health, wellness
and anti-aging internally and externally at the cellular level. The company is
the maker of the Protandim(®) line of scientifically validated dietary
supplement, the TrueScience(®) Anti-Aging Skin Care Regimen, Canine Health(®),
the AXIO(®) energy product line and the PhysIQ(TM) smart weight management
system. LifeVantage was founded in 2003 and is headquartered in Salt Lake City,
Utah.
www.lifevantage.com
Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. Words
and expressions reflecting optimism, satisfaction or disappointment with current
prospects, as well as words such as "believe," "hopes," "intends," "estimates,"
"expects," "projects," "plans," "anticipates," "look forward to" and variations
thereof, identify forward-looking statements, but their absence does not mean
that a statement is not forward-looking. Examples of forward-looking statements
include, but are not limited to, statements we make regarding our future growth
and distributor success. Such forward-looking statements are not guarantees of
performance and the Company's actual results could differ materially from those
contained in such statements. These forward-looking statements are based on the
Company's current expectations and beliefs concerning future events affecting
the Company and involve known and unknown risks and uncertainties that may cause
the Company's actual results or outcomes to be materially different from those
anticipated and discussed herein. These risks and uncertainties include, among
others, those discussed in greater detail in the Company's Annual Report on Form
10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk
Factors," and in other documents filed by the Company from time to time with
the Securities and Exchange Commission. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in this
document. All forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to reflect
events or circumstances after the date of this document, except as required by
law.
Company Relations Contact:
John Genna (801) 432-9172
Vice President of Communications
& Corporate Partnerships
Investor Relations Contacts:
Cindy England (801) 432-9036
Director of Investor Relations
-Or-
Scott VanWinkle (617) 956-6736
Managing Director, ICR
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: LifeVantage Corporation via GlobeNewswire
[HUG#2032445]
Unternehmensinformation / Kurzprofil:
Datum: 02.08.2016 - 15:00 Uhr
Sprache: Deutsch
News-ID 486819
Anzahl Zeichen: 5953
contact information:
Town:
Sandy
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 336 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NIA Study Confirms Protandim Nrf2 Synergizer Extends Life"
steht unter der journalistisch-redaktionellen Verantwortung von
LifeVantage Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
